01 4Aimix
02 6Amlodin
03 1Caduet
04 4Exforge
05 4Exforge Group
06 8Norvasc
07 1Norvase
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 65
2019 Revenue in Millions : 76
Growth (%) : -15
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 950
2018 Revenue in Millions : 1,029
Growth (%) : -8
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 980
2019 Revenue in Millions : 1,025
Growth (%) : -4
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 50
2020 Revenue in Millions : 65
Growth (%) : -12
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 901
2020 Revenue in Millions : 980
Growth (%) : -8
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 743
2021 Revenue in Millions : 901
Growth (%) : -18
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 775
2021 Revenue in Millions : 825
Growth (%) : -6
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 713
2022 Revenue in Millions : 743
Growth (%) : -4
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 732
2022 Revenue in Millions : 775
Growth (%) : -6
Upjohn (9 months)
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 601
2019 Revenue in Millions : 735
Growth (%) : -18
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
LOOKING FOR A SUPPLIER?